B-cell Precursor Acute Lymphoblastic Leukemia
📧 Sign up to get email alerts when something new happens for B-cell Precursor Acute Lymphoblastic Leukemia.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2025-11-06EMA Authorised: Kymriah (tisagenlecleucel) — Novartis Europharm Limited
The EMA authorised Kymriah (tisagenlecleucel) for additional indications in precursor B-cell lymphoblastic leukemia/lymphoma and diffuse lar…
-
FDA approval · 2025-04-29FDA Approved: BLINCYTO — Supplemental Application (Amgen, Inc)
The FDA approved a supplemental application for BLINCYTO (blinatumomab) from Amgen, Inc., updating labeling and/or expanding the approved in…
-
FDA approval · 2019-04-18FDA Approved: BLINCYTO — Supplemental Application (Amgen, Inc)
The FDA approved a supplemental application for BLINCYTO (blinatumomab) submitted by Amgen, signaling an update to labeling and/or indicatio…
-
FDA approval · 2014-12-03FDA Approved: BLINCYTO — Original Application (Amgen, Inc)
The FDA approved BLINCYTO (blinatumomab) from Amgen as an original application. It is a novel bispecific T-cell engager indicated for relaps…